Physiological and molecular effects of Apo2L/TRAIL and cisplatin in ovarian carcinoma cell lines (Q38358514)

2 September 2017

Physiological and molecular effects of Apo2L/TRAIL and cisplatin in ovarian carcinoma cell lines (English)

1 reference

2 September 2017

1 reference

1 reference

Siervo-Sassi RR

1

1 reference

2 September 2017

Marrangoni AM

2

1 reference

2 September 2017

Feng X

3

1 reference

2 September 2017

Naoumova N

4

1 reference

2 September 2017

Winans M

5

1 reference

2 September 2017

Edwards RP

6

1 reference

2 September 2017

Lokshin A

7

1 reference

2 September 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

2 September 2017

1 reference

2 September 2017

190

1 reference

2 September 2017

1

1 reference

2 September 2017

61-72

1 reference

Ovarian cancer: epidemiology, biology, and prognostic factors

2 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900579-7

7 January 2021

Epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900579-7

7 January 2021

Epithelial ovarian cancer: prevention, diagnosis, and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900579-7

7 January 2021

Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900579-7

7 January 2021

Apoptosis control by death and decoy receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900579-7

7 January 2021

Intracellular mechanisms of TRAIL and its role in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900579-7

7 January 2021

TRAIL/Apo-2L: mechanisms and clinical applications in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900579-7

7 January 2021

Death receptors and apoptosis. Deadly signaling and evasive tactics

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900579-7

7 January 2021

Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900579-7

7 January 2021

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900579-7

7 January 2021

Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900579-7

7 January 2021

FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900579-7

7 January 2021

Apoptosis signaling by death receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900579-7

7 January 2021

Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900579-7

7 January 2021

Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900579-7

7 January 2021

Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inh

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900579-7

7 January 2021

Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900579-7

7 January 2021

Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900579-7

7 January 2021

Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900579-7

7 January 2021

Trail activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900579-7

7 January 2021

Safety and antitumor activity of recombinant soluble Apo2 ligand

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900579-7

7 January 2021

Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: analysis with the NONMEM program

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900579-7

7 January 2021

Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900579-7

7 January 2021

Tumor necrosis factor receptor and Fas signaling mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900579-7

7 January 2021

Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900579-7

7 January 2021

The Bcl-2 protein family

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900579-7

7 January 2021

The short splice form of Casper/c-FLIP is a major cellular inhibitor of TRAIL-induced apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900579-7

7 January 2021

10.1016/S0304-3835(02)00579-7

Identifiers

DOI

1 reference

2 September 2017

1 reference